Compass Therapeutics Inc. (CMPX) — Cash Flow-to-Debt Ratio
Compass Therapeutics Inc. (CMPX) has a Cash Flow-to-Debt Ratio of -0.92x as of March 2026, meaning its operating cash flow of $-17.27 Million could theoretically repay -1% of its total liabilities ($18.70 Million) in one year. Explore cash flow conversion of Compass Therapeutics Inc. to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Compass Therapeutics Inc. Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Compass Therapeutics Inc. across 8 annual periods. Also explore CMPX total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Compass Therapeutics Inc. (2018–2025)
Year-by-year debt coverage analysis for Compass Therapeutics Inc.. For market capitalisation and broader financial context, see CMPX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.16x | $-49.14 Million | $22.80 Million | ▲ +27.1% |
| 2024 | -2.96x | $-44.85 Million | $15.17 Million | ▲ +39.3% |
| 2023 | -4.87x | $-40.62 Million | $8.34 Million | ▼ -157.1% |
| 2022 | -1.90x | $-34.12 Million | $18.01 Million | ▼ -31.8% |
| 2021 | -1.44x | $-19.67 Million | $13.68 Million | ▲ +35.8% |
| 2020 | -2.24x | $-26.80 Million | $11.97 Million | ▼ -951.4% |
| 2019 | -0.21x | $-31.74 Million | $148.98 Million | ▲ +5.5% |
| 2018 | -0.23x | $-33.68 Million | $149.40 Million | — |